Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of STL303 in adults with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. GA leads to gradual cell death in the back of the eye, causing blurry or missing central vision spots. This randomized, double-masked, multi-center study aims to find the best dose of STL303 and assess its impact on this eye condition. Participants will be randomly assigned to receive either one of two doses of oral STL303 or a placebo. The study compares these groups to understand how STL303 affects the rate of vision loss and other eye health measures. The treatment period lasts up to 104 weeks, with evaluations continuing through week 108 to monitor safety and disease progression. During the study, participants will undergo regular eye exams, including imaging scans and vision tests, to track changes in their condition. Researchers will measure the reduction in the area of eye damage, retinal sensitivity, and vision-related quality of life. Blood samples will be collected at scheduled visits to analyze how the drug is processed in the body. Participants will also record daily medication use and attend frequent study visits for assessments and safety monitoring. The total trial participation may last several years until study completion in 2029.
Actively Recruiting
Researchers are studying the safety and effectiveness of tabirafusp tedromer compared to aflibercept in people with diabetic macular edema DME, a condition causing vision impairment related to diabetes. This phase 3 randomized trial aims to evaluate these two treatments administered by injection into the eye, focusing on improving vision clarity. Participants receive intravitreal injections of either tabirafusp tedromer or aflibercept. Tabirafusp tedromer is given once every 4 weeks for six doses, then either every 8 weeks or individualized between every 4 to 24 weeks depending on the group. Aflibercept is administered every 4 weeks for five doses, followed by every 8 weeks. The study compares these dosing schedules over time to assess treatment impact. During the trial, participants undergo regular eye exams to measure best corrected visual acuity at week 52 and other safety assessments. The study includes monitoring of treatment effects and side effects through scheduled visits with injections and vision tests. Participation lasts through the treatment and evaluation period, allowing researchers to gather data on vision changes and overall safety.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate the use and safety of Motiva Implants in people undergoing breast implant procedures. The study focuses on collecting and assessing safety and effectiveness data about these implants after they have been approved and are in general use. It includes participants who have primary breast augmentation, revision breast augmentation, or other aesthetic surgeries, with a focus on female patients aged 22 and older. Participants will receive Motiva Implants as part of their breast surgery or undergo other aesthetic procedures. The study is prospective and non-randomized, with data collected at baseline before surgery, during the operation, and annually for up to 10 years after surgery. Participants who have revision surgery or other aesthetic procedures without implants are also included as control groups to compare outcomes. During the study, participants will have various assessments including medical imaging such as CT, ultrasound, or MRI if medically advised. Researchers will monitor for connective tissue disease signs and symptoms, reproductive complications, cancer diagnoses, local complications, and patient satisfaction over 10 years. The impact of RFID on imaging will also be assessed. Participants will be followed for up to 10 years, providing long-term data on the safety and performance of Motiva Implants.
Actively Recruiting
Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.